Our Heritage

We're proud of our heritage in drug development.

With over 30 years of experience, we are a trusted integrated CRDMO partner for all stages of small molecule drug development and synthetic peptide drug development. What really excites us is the future and continuing our journey of helping customers get new treatments to patients, faster.

Founded in 1990, Pharmaceutical Profiles was established as a spin-out from the University of Nottingham and the Royal Free Hospital, London, UK. It was an early-phase development company that helped improve decisions in early drug development. The company's mission was to improve the drug development decision-making process by offering innovative services to select the right molecules in early development.

In 2002, QS Pharma was founded, specializing in formulation development and manufacturing of small molecule drug products. The company supported pharma and biotech customers through all stages of development and commercialization.

In 2008, Quotient BioResearch acquired BioDynamics Research Limited. Founded over 15 years prior, BioDynamics was a specialist provider of metabolism, bioanalytical, and radiochemistry services worldwide. 

Pharmaceutical Profiles joined the Quotient Bioscience Group Limited in 2008. With capabilities for GMP manufacturing and GCP clinical trials in Nottingham, UK, Quotient Bioresearch developed RapidFACT, a novel formulation optimization approach.

In May 2009, Quotient Bioresearch acquired the Edinburgh clinical research facility (formerly Inveresk Clinical Research) from Charles River Laboratories. Combined with the services and capabilities from Pharmaceutical Profiles, a new business was formed: Quotient Clinical.

Quotient Clinical expanded its footprint into the United States with the acquisitions of two organizations: SeaView Research, a specialist clinical pharmacology and contract research services provider (CRO) in Miami, Florida, and QS Pharma, a contract development and manufacturing organization (CDMO) in the Philadelphia, Pennsylvania metropolitan area.  

These acquisitions helped expand the company into the United States, furthering capabilities for integrated drug development with both clinical and manufacturing capabilities under one organization.

At the time, former CEO Mark Egerton commented, "We are excited about the future of Quotient Sciences. By integrating services typically found in disparate CDMO and CRO businesses, we break down barriers and support our customers to improve R&D productivity and accelerate the delivery of new medicines to patients around the world. We have a 30-year track record of service to a global customer base, including large multinational pharmaceutical companies to smaller virtual biotech organizations."

Following these acquisitions, Quotient Clinical announced that the company was renaming to Quotient Sciences.

In early 2021, Quotient Sciences acquired Arcinova, a UK based multiservice contract development and manufacturing organization (CDMO). The acquisition expanded the company's offering with the addition of drug substance, bioanalytical testing, and other capabilities offered from the company's Alnwick, UK location. 

Across 2022 and 2023, the company expanded the Alnwick, UK facility further with new equipment and capacity added for sterile fill and finish of parenteral drugs. 

In June 2025, Quotient Sciences announced the re-launch of Arcinova, A Quotient Sciences Company, combining capabilities from Alnwick and Reading, UK for a streamlined approach to early drug development.